Rieske P. Vaccine against COVID-19 or against SARS-CoV-2 infection?. Alergologia Polska - Polish Journal of Allergology. 2020;7(3):131-145. doi:10.5114/pja.2020.97913.
APA
Rieske, P. (2020). Vaccine against COVID-19 or against SARS-CoV-2 infection?. Alergologia Polska - Polish Journal of Allergology, 7(3), 131-145. https://doi.org/10.5114/pja.2020.97913
Chicago
Rieske, Piotr. 2020. "Vaccine against COVID-19 or against SARS-CoV-2 infection?". Alergologia Polska - Polish Journal of Allergology 7 (3): 131-145. doi:10.5114/pja.2020.97913.
Harvard
Rieske, P. (2020). Vaccine against COVID-19 or against SARS-CoV-2 infection?. Alergologia Polska - Polish Journal of Allergology, 7(3), pp.131-145. https://doi.org/10.5114/pja.2020.97913
MLA
Rieske, Piotr. "Vaccine against COVID-19 or against SARS-CoV-2 infection?." Alergologia Polska - Polish Journal of Allergology, vol. 7, no. 3, 2020, pp. 131-145. doi:10.5114/pja.2020.97913.
Vancouver
Rieske P. Vaccine against COVID-19 or against SARS-CoV-2 infection?. Alergologia Polska - Polish Journal of Allergology. 2020;7(3):131-145. doi:10.5114/pja.2020.97913.
Article offers analysis of main aspects of SARS-CoV-2/COVID-19 vaccination (severe acute respiratory syndrome coronavirus 2/COVID-19-Coronavirus Disease 2019). Optimal vaccine should protect not only against disease COVID-19 (symptoms), but also against SARS-CoV-2 infection (spreading disease). However, this kind of vaccine – showing highest safety level is extremely difficult to get. Several additional SARS-CoV-2/COVID-19 vaccination issues were addressed in article. For example: serological passports, herd immunity, clinical trials, and role of antibodies and T cells crossreactivities. Article discusses some issues related to vaccination responsibilities.
